FDA gives PCSK9 inhibitor priority review

The FDA granted priority review status to alirocumab, a monoclonal antibody designed to reduce low-density lipoprotein (LDL) cholesterol in statin-intolerant patients.

Regeneron Pharmaceuticals and Sanofi announced the FDA's decision, which puts the target action date at July 24. Alirocumab (Praluent) inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and is intended as a treatment of patients with hypercholesterolemia.

Safety and efficacy results from ODYSSEY ALTERNATIVE were presented at the 2014 meeting of the American Heart Association. The trial was an international, randomized, double-blind, double-dummy placebo-controlled study. It enrolled patients who were very high-, high- or moderate-risk who had a history of statin intolerance, which was defined as the inability to tolerate at least two different statins because of skeletal-muscle symptoms, with one of the statins at the lowest approved starting dose.

At 24 weeks, the alirocumab group had a 45 percent reduction in LDL cholesterol. Fewer patients in the alirocumab group reported skeletal-muscle-related treatment-emergent adverse events than in the other groups.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup